- Sub-, extra- or juxta-foveal choroidal neovascularization (CNV) or macular scar due to
AMD in the non-study eye.
- No CNV or geographic atrophy in the study eye.
- Best corrected visual acuity in the study eye of greater than 20/40 or better than 70
- Sufficiently clear ocular media and adequate pupillary dilatation to permit good
quality fundus imaging of the study eye.
- Subjects of either sex, aged 50 years.
- Evidence of a signed and dated informed consent document indicating that the subject
(or a legally acceptable representative) has been informed of all pertinent aspects of
- Willing and able to comply with scheduled visits, laboratory tests, and other trial
- Subjects presenting with any of the following will not be included in the study:
- Evidence of manifest CNV by FA, color photography or ICG angiography in the study eye.
- Any prior treatment for CNV to the study eye (excluding vitamins and AREDS formula).
- Significant media opacities, including cataract, which might interfere with visual
acuity assessments, or fundus imaging in the study eye. Subjects should not be entered
if there is likelihood that they will require cataract surgery within the following 2
- Presence of other causes of choroidal neovascularization in the fellow eye, including
pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial
length of 25 mm or more), the ocular histoplasmosis syndrome, angioid streaks,
choroidal rupture, and multifocal choroiditis.
- Any progressive eye disease other than AMD (eg, glaucoma, diabetic retinopathy) in the
- Presence of subretinal hemorrhage, serous or hemorrhagic pigment epithelial
detachments, subretinal fibrosis or pigment epithelial tears or rips in the study eye.
- Any medical condition that would interfere with the patient's ability to complete the
- Concurrent enrollment in any other observational or interventional clinical study.
- Any treatment with an ocular or systemic investigational agent in the past 60 days for
any medical condition.
- Known serious allergies to the dye used in fluorescein angiography or ICG.